key: cord-0761015-pspko62f
authors: Aul, Raminder; Gates, Jessica; Draper, Adrian; Dunleavy, Anne; Ruickbie, Sachelle; Meredith, Helen; Walters, Nicola; van Zeller, Cristiano; Taylor, Victoria; Bridgett, Michael; Dunwoody, Roisin; Grubnic, Sisa; Jacob, Tersesa; Ean Ong, Yee
title: Complications after Discharge with COVID-19 Infection and Risk Factors Associated with Development of Post-COVID Pulmonary Fibrosis
date: 2021-09-08
journal: Respir Med
DOI: 10.1016/j.rmed.2021.106602
sha: 0989107402fc9f871fa5b14f54f0d2dff2fb2634
doc_id: 761015
cord_uid: pspko62f

Introduction: Survivors of COVID-19 infection may develop post-covid pulmonary fibrosis (PCF) and suffer from long term multi-system complications. The magnitude and risk factors associated with these are unknown. Objectives: We investigated the prevalence and risk factors associated with PCF and other complications in patients discharged after COVID-19 infection. Methods: Patients had phone assessment 6 weeks post hospital discharge after COVID-19 infection using a set protocol. Those with significant respiratory symptoms were investigated with a CTPA, Pulmonary Function Tests and echocardiogram. Prevalence of myalgia, fatigue, psychological symptoms and PCF was obtained. Risk factors associated with these were investigated. Results: A large number of patients had persistent (45.1%) fatigue, breathlessness (36.5%), myalgia (20.5%) and psychological symptoms (19.5%). PCF was seen in 9.5% of the patients and was associated with persistent breathlessness at 6 weeks and inpatient ventilation [adjusted OR 5.02(1.76-14.27) and 4.45(1.27-15.58)] respectively. It was more common in men and in patients with peak CRP >171.5 mg/L, peak WBC count ≥12 x 10 9/L, severe inpatient COVID-19 CXR changes and CT changes. Ventilation was also a risk factor for persisting fatigue and myalgia, the latter was also more common in those with severe cytokine storm and severe COVID-19 inpatient CXR changes. Conclusions: All the patients discharged after COVID-19 should be assessed using a set protocol by a multidisciplinary team. Patients who had severe COVID-19 infection particularly those who were intubated and who have persistent breathlessness are at risk of developing PCF. They should have a CT Chest and have respiratory follow-up.

The COVID-19 pandemic has been the biggest challenge facing the world in modern times. Globally more than 69 million cases and 1.5 million deaths have been recorded as of 10/12/2020 1 . The initial focus has rightly been on the provision of health care facilities and developing treatments for hospitalised COVID-19 patients. There have been encouraging results with Dexamethasone 2 and Remdesevir 3, 4 in reducing mortality and morbidity respectively. As survival improves, the next challenge we face is identifying and managing longer term complications of COVID-19 infection. 5, 6 There are indications that a significant number of COVID-19 survivors develop longer term respiratory 7-9 cardiovascular 10 and psychological 11 sequalae. Many patients also suffer from fatigue, myalgia and memory impairment. [12] [13] [14] There is a need to identify the magnitude of these complications so that health care resources can be suitably allocated. 5 There is a particular concern that a proportion of the patients could develop post-COVID fibrosis (PCF) in their lungs similar to the survivors of MERS and SARS-CoV1. 8, 15, 16 Patients developing pulmonary fibrosis often suffer from progressive breathlessness and need long term follow up. 17 There is a need to identify risk factors for developing PCF so that those at risk can be promptly investigated and managed or entered into future therapeutic clinical trials.

In May 2020, the British Society of Thoracic Imaging (BSTI) published codes (0-3) for assessing and reporting post-COVID changes on CT scans. 18 This has helped in providing standardisation while reporting the CT scans and identifying post-COVID fibrosis on thoracic CT scans.

Eight hundred and ninety-eight patients were admitted to our institution with COVID-19 between March and July 2020. We developed a pathway for the follow-up of patients discharged after COVID-19 infection which is presented in this observational study. We have also described the persisting symptoms and the magnitude of systemic effects, particularly PCF, in our cohort. We have further identified risk factors associated with the development of PCF.

All patients admitted to our hospital with COVID-19 (defined as admission to an acute inpatient bed, with either a positive SARS-COV2 naso-pharyngeal swab on RT-PCR, or a clinico-radiological diagnosis of COVID-19), were identified. We developed a pathway for the outpatient follow up of all the patients who were successfully discharged.

Patients deemed unable to manage a phone consultation (those with significant memory loss, nursing home residents and those patients who were discharged with a palliative intent) were excluded. The rest of the patients were offered a phone consultation with a respiratory physician 6 weeks after discharge. The patients who answered the phone consultation were included. The patients who could not be contacted over the phone were further excluded from this analysis. We wrote to the general practitioners of all the excluded patients asking them to refer the patients back to us if there was a concern in the community.

J o u r n a l P r e -p r o o f

We used a standardised proforma to assess the patients which is described in the supplement. We collected laboratory investigation data during the inpatient admission with COVID-19 particularly, the peak levels of CRP, ferritin, D-dimer, WBC and the lowest lymphocyte count which were used as biomarkers of cytokine storm. Chest X rays during their inpatient stay were reviewed and the worst CXR was divided into low and high risk as described by Toussie et al. 19 Those patients who were clinically judged to have persistent significant respiratory symptoms were investigated with a CTPA with high resolution reconstruction, PFT and echocardiogram and offered a follow-up outpatient appointment with a respiratory consultant.

Patients without respiratory symptoms at the time of the phone clinic were asked to have a follow up CXR 10 weeks after discharge if they had COVID-19 changes on their inpatient CXR. If this CXR showed persistent changes, they were investigated and reviewed using the same pathway as the symptomatic patients. The rest of the patients were discharged from respiratory follow up and referred to appropriate other specialities if required.

Second outpatient assessment CTPA, PFT and echocardiogram findings were reviewed. CT chest was reported by two thoracic radiologists and the post-COVID pulmonary changes were coded as PCVCT0-3 as per the BSTI coding. 18 Only those patients whose CT scans showed established fibrosis ± ground glass abnormalities (PCVCT3) were classified as having post-COVID J o u r n a l P r e -p r o o f fibrosis. The extent of the interstitial abnormality on both this (follow up) and the worst inpatient CT chest was scored between 0-25, a score ≥18 was classified as high risk CT, as described previously 20 . This scoring was performed by an experienced respiratory consultant with an interest in interstitial lung diseases.

We estimated the persistent disease burden by calculating the number of patients with anxiety, depression, fatigue, myalgia and PCF. We assessed the association of PCF, fatigue and myalgia with a number of variables including demographics (gender, race, age and BMI), markers of cytokine storm, high risk inpatient CXR, history of ICU admission and invasive ventilation use during the inpatient stay. The following additional factors were also assessed for association with the development of PCFpremorbid respiratory disease, co-morbidities (diabetes, hypertension, ischemic heart disease, chronic liver disease and history of long term dialysis), smoking status, inpatient CT score, PFT parameters, MRC, ΔMRC (Difference in post and pre-COVID MRC dyspnoea scores), CAT score and persistent symptoms. The association between the inpatient and outpatient CT chest score was also assessed.

Data analysis was performed using STATA version 16.1. 21 The categorical data is expressed as frequency (%) and compared using the Chi-squared test. Univariate logistic regression analysis was undertaken to examine associations with significant outcomes. Results are expressed as odds ratio (OR) and 95% confidence intervals (CI).

Continuous data is presented as medians (interquartile range) and compared using the Mann-Whitney U test. Optimal cut points for discriminating outcomes with significant J o u r n a l P r e -p r o o f differences were determined using the Liu method, 22 J o u r n a l P r e -p r o o f (Table 3) J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Persistent fatigue was associated with ICU admission and strongly associated with invasive ventilation, OR 3.1 (1.72-5.6) ( Table 5 ). Although patients with fatigue had a lower median BMI (26.5) compared to those without fatigue (28.9), this is not clinically significant as both lie in the overweight range. There was no significant association seen with any of the other studied variables although there was a trend towards a higher CRP in the fatigued patients. ICU admission was no longer significant when adjusted for invasive ventilation.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 1 12 ( Society's guidance suggests using a CXR 12 weeks post discharge, with a further clinical assessment recommended only in those with persistently abnormal x-rays or those patients who needed critical care admission. 24 However, a recent study has shown that a follow up x-ray on its own is insufficient for assessing recovery in post-COVID patients as many patients with a normal CXR have a significant symptom burden 25 . In this study we have described a simple holistic outpatient follow up pathway, which uses an initial phone clinic to assess symptoms and targeting investigations in symptomatic patients with onward referral to appropriate specialities for timely management.

A large number (36.5%) of patients suffer from persistent breathlessness, many patients also have fatigue, myalgia, and psychological symptoms 6 weeks after discharge from COVID-19 infection. This is similar to the results seen in other studies. 12,13,,26,27 The degree of breathlessness is moderate to severe with a median MRC dyspnea score of 3

(2-4), which was an average of 1(0-2) point higher than the pre-COVID score. We also found that a majority of the patients (56.3%) had difficulty in estimating their MRC dyspnea score because they had not started to exercise or go outdoors since discharge from hospital. CAT score has been validated in assessing symptom burden in patients with COPD and IPF [28] [29] [30] , patients in this study were able to estimate this score easily.

We found that CAT score ≥10 was useful in predicting risk of developing post-COVD fibrosis, making it a useful simple tool in assessing respiratory symptoms in this setting.

As post-COVID-19 patients have a diverse symptom burden, they should be assessed in a multi-disciplinary clinic comprising of respiratory physicians, physiotherapists, occupational therapists and psychologists.

Estimation of Post-COVID Fibrosis 9.3% of our study population had post-COVID fibrosis. One study has described prevalence of post-COVID pulmonary abnormalities on CT in 63% of the patients, no patient in that study had pulmonary fibrosis 27 . Other studies from previous pandemics have shown that at 12 months there is 20-45% prevalence of pulmonary fibrosis on CT scans after H7N9 31 and SARS 32 respectively. The higher rate reported in these studies is likely because these studies did not use specific criteria to define interstitial changes and fibrosis. Our study is the first study to specifically describe prevalence of post-COVID-19 fibrotic lung disease as we selected patients with definite fibrotic change on CT (PCVCT3 changes as per BSTI coding 18 ). The extent of interstitial abnormalities on the outpatient follow up CT Chest (CT score) was related to the COVID-19 inpatient CT score (r=0.58). It is difficult to be certain whether these changes will persist or resolve with time and longer term follow up over a year will be useful. This is one of the reasons why we did not classify patients with isolated ground glass changes (PCVCT1 and 2) as having PCF.

Patients with PCF had a moderate reduction in DLCOc, only mild reduction in TLC and had a normal FVC. Other studies have also shown that changes in DLCO are most J o u r n a l P r e -p r o o f sensitive in predicting post-COVID pulmonary disease. 27, 33 Therefore, spirometry on its own is insufficient for screening for PCF. Gas transfers are essential if lung physiology is used as a screening tool, this is challenging because these require trained physiologists and access to lung function is restricted due to cross-infection risk.

Similar to a previous study 27 we only found 2 (0.5%) new cases of PE in our study and these patients had high risk factors for thrombo-embolism. One of these had deep vein thrombosis few weeks before the CTPA and the other had suspected gall bladder cancer. This is in contrast to a higher incidence of PE in acute COVID-19 infection 34 .

The low incidence is likely to be due to prompt diagnosis, management and widespread use of thrombo-prophylaxis during acute COVID. Therefore, non-contrast HRCT would suffice as the imaging modality in this cohort and CTPA can be reserved for patients with a high risk of PE.

Only 1.2% patients were found to have LV dysfunction in our study which is similar to another recent study 27 We did not include any questionnaires to screen for memory impairment as we were apprehensive that these would be difficult to administer over the phone. Similarly, we do not have data on Vitamin D levels in our study. Vitamin D deficiency may be a risk factor associated with long term complications of COVID-19 particularly fatigue. We would suggest that post-COVID-19 follow up protocols include screening for memory impairment 25, 48 and assess Vitamin D levels especially in those with persistent fatigue and myalgia.

We did not use 6-minute walk test 49 or 1-minute sit-stand test 50 to screen patients for further cardio-respiratory investigations as these require a face to face encounter. There may be a role of these tests in screening patients for PCF and need further research.

We performed CTPA with high resolution reconstruction in this study. CTPA was chosen as the imaging modality so that we did not miss pulmonary emboli. We acknowledge that the contrast used in CTPA can sometimes give a false impression of ground glass change on the images, but it does not over estimate tractional bronchiectasis, the presence of which is necessary for the CT scans to be classified as PCVCT3 (the criteria used in this study to define PCF). Therefore, the radio-contrast and imaging modality of CTPA instead of high resolution CT Chest would not affect the accuracy of assessment of PCF. We are confident that we screened the patients meticulously and only those patients who had no respiratory symptoms and no COVID-19 changes on their inpatient or follow up CXR did not have CT imaging. It is unlikely that these patients would have PCF.

Conclusions:

Patients discharged from hospital after COVID-19 infection should be screened with standardised questionnaires (such as used in this paper) for respiratory symptoms, fatigue, myalgia and psychological disorders. Questions directed at screening for memory impairment should also be incorporated.

As these patients have a large and diverse symptom burden, they should be managed by a MDT comprising of respiratory physicians, physiotherapists, occupational therapists and psychologists with access to other specialities as needed.

All patients who received invasive ventilation and those who have persistent breathlessness (especially men), those who had high risk inpatient CXR, high inpatient CT scores and high markers of cytokine storm (CRP >171.5 mg/L and WBC ≥ 12 x 

An interactive web-based dashboard to track COVID-19 in real time

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Follow-up studies in COVID-19 recovered patients -is it mandatory?

COVID-19 follow-up planning: what will we be missing?

Long term respiratory complications of covid-19

Respiratory follow-up of patients with COVID-19 pneumonia

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19)

Predictors of Health-Related Quality of Life and Influencing Factors for COVID-19 Patients, a Follow-Up at One Month. Front Psychiatry

Long-COVID": A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

Persistent symptoms in patients after acute COVID-19

Follow-up of adults with non-critical COVID-19 two months after symptoms' onset

Long-term Pulmonary Consequences of Coronavirus Disease 2019 (COVID-19): What We Know and What to Expect

Long-term clinical outcomes in survivors of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis

American Thoracic Society Idiopathic Pulmonary Fibrosis : Diagnosis and Treatment

Clinical and chest radiography features determine patient outcomes in young and middle-aged adults with COVID-19

Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis

StataCorp. Stata Statistical Software: Release 16

Classification accuracy and cut pointselection

Guidance for using patient data. NHS Health Research Authority

British Thoracic Society Guidance on Respiratory Follow Up of Patients with a Clinico-Radiological Diagnosis of COVID-19 Pneumonia

Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia

The pulmonary sequalae in discharged patients with COVID-19: A short-term observational study

Cardiopulmonary recovery after COVID-19 -an observational prospective multi-center trial

Evaluation of the chronic obstructive pulmonary disease assessment test for measurement of health-related quality of life in patients with interstitial lung disease

Clinical application of the COPD assessment test (CAT) in patients with idiopathic pulmonary fibrosis

Minimum clinically important difference for the COPD Assessment Test: A prospective analysis

Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection

Follow-up Study on Pulmonary Function and Lung Radiographic Changes in Rehabilitating Severe Acute Respiratory Syndrome Patients After Discharge

Respiratory function in patients post-infection by COVID-19: a systematic review and metaanalysis

Computed tomography characterization and outcome evaluation of COVID-19 pneumonia complicated by venous thromboembolism

Clinical features of patients infected with

Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area

Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Hear Rhythm

The 2019-2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american. college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper

Survival in adult inpatients with COVID-19

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

Impact of severe acute respiratory syndrome J o u r n a l P r e -p r o o f (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: Preliminary experience

Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review

Mild versus severe COVID-19: Laboratory markers

Initial chest radiographs and artificial intelligence (AI) predict clinical outcomes in COVID-19 patients: analysis of 697

Chest X-ray for predicting mortality and the need for ventilatory support in COVID-19 patients presenting to the emergency department

COVID-19: consider cytokine storm syndromes and immunosuppression

Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19

ATS Statement : Guidelines for the Six-Minute Walk Test

A multicentre validation of the 1-min sit-tostand test in patients with COPD